Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Oppenheimer Adjusts Exelixis' Price Target to $29 From $30, Maintains Outperform Rating

11/02/2021 | 08:05am EST


ę MT Newswires 2021
All news about EXELIXIS, INC.
01/19Exelixis Reports Trial Results For Cabozantinib in Combination With Immunotherapies to ..
MT
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
BU
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
CI
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Prov..
PU
01/10EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/10Exelixis Expects Net Product Revenue of $300 Million for Q4, $1.08 Billion for Full-Yea..
MT
01/09Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Pro..
BU
01/09Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter a..
CI
01/06Exelixis to Pay $55 Million to Amend Licensing Deal With Iconic Therapeutics, Gains Ful..
MT
01/06Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antib..
BU
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2021 1 342 M - -
Net income 2021 165 M - -
Net cash 2021 1 019 M - -
P/E ratio 2021 37,4x
Yield 2021 -
Capitalization 5 762 M 5 762 M -
EV / Sales 2021 3,53x
EV / Sales 2022 2,85x
Nbr of Employees 773
Free-Float 97,9%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 18,52 $
Average target price 28,85 $
Spread / Average Target 55,8%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.-5.25%5 860
GILEAD SCIENCES, INC.-5.56%86 013
REGENERON PHARMACEUTICALS-1.60%64 979
VERTEX PHARMACEUTICALS4.59%58 397
WUXI APPTEC CO., LTD.-7.49%51 604
BIONTECH SE-41.44%36 465